Olema Pharmaceuticals, Inc. — Director's Dealing 2021

Nov 12, 2021

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Olema Pharmaceuticals, Inc. (OLMA)
CIK: 0001750284
Period of Report: 2021-11-10

Reporting Person: Horn Kinney (N/A)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2021-11-10	Common Stock	M	5251	$2.064	Acquired	7041	Direct
2021-11-10	Common Stock	M	22417	$19	Acquired	29458	Direct
2021-11-10	Common Stock	S	27668	$26.88	Disposed	1790	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2021-11-10	Stock Option (Right to Buy)	$2.064	M	5251	Disposed	2030-06-09	Common Stock (5251)	Direct
2021-11-10	Stock Option (Right to Buy)	$19	M	22417	Disposed	2030-11-09	Common Stock (22417)	Direct

Footnotes

F1: The sales reported in this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the reporting person.

F2: T he weighted average sale price for the transaction reported was $26.88, and the range of prices was between $26.56 and $27.32. Upon request from the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price will be provided.

F3: The shares subject to the option vest in a series of 48 successive equal monthly installments measured from June 10, 2020, subject to the Reporting Person's continuous service through each applicable vesting date.

F4: One thirty-sixth of the remaining number of shares subject to the option vest on a monthly basis, subject to the Reporting Person's continuous service through each applicable vesting date.